https://beta.crstoday.com/news/new-research-reveals-covid-19-virus-could-damage-vision/2482285/daily0.7https://beta.crstoday.com/news/drug-farm-gets-green-light-from-fda-to-initiate-phase-1b-trial-of-df-003-in-rosah-syndrome-patients/2482284/daily0.7https://beta.crstoday.com/news/reichert-launches-tono-vera-tonometer-in-the-us/2482283/daily0.7https://beta.crstoday.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/daily0.7https://beta.crstoday.com/news/haag-streit-launches-3d-imaging-option-for-the-imaging-module-910/2482281/daily0.7https://beta.crstoday.com/news/proposed-bipartisan-legislation-would-create-first-federally-funded-program-to-address-childrens-vision-and-eye-health/2483743/daily0.7https://beta.crstoday.com/news/arcscans-insight-100-ophthalmic-ultrasound-imaging-system-approved-in-china/2482279/daily0.7https://beta.crstoday.com/news/beyeonics-vision-installs-first-beyeonics-one-digital-exoscope/2482278/daily0.7https://beta.crstoday.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/daily0.7https://beta.crstoday.com/news/oculis-completes-enrollment-in-phase-2-randomized-controlled-acuity-trial-with-ocs-05-for-acute-optic-neuritis/2483742/daily0.7https://beta.crstoday.com/news/topcon-healthcare-partners-with-microsoft-to-deliver-ai-powered-healthcare-from-the-eye/2482274/daily0.7https://beta.crstoday.com/news/revopsis-names-emmett-cunningham-md-phd-to-strategic-advisory-board/2482273/daily0.7https://beta.crstoday.com/news/bausch-lomb-launches-zenlens-echo-scleral-lenses-in-the-united-states/2482272/daily0.7https://beta.crstoday.com/news/alcon-to-acquire-israel-based-belkin-vision-maker-of-eagle-slt-laser/2482270/daily0.7https://beta.crstoday.com/news/staar-surgical-announces-agreement-in-us-with-iq-laser-vision/2482269/daily0.7https://beta.crstoday.com/news/ior-partners-co-founder-and-chairman-of-the-board-daniel-s-durrie-md-retires/2482267/daily0.7https://beta.crstoday.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/daily0.7https://beta.crstoday.com/news/ora-and-singapore-eye-research-institute-unveil-partnership-to-propel-ophthalmology-innovation-globally/2482264/daily0.7https://beta.crstoday.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/daily0.7https://beta.crstoday.com/news/lumibird-launches-cdiag-dry-eye-diagnostic-aid-platform-platform/2482260/daily0.7https://beta.crstoday.com/news/safilo-north-america-appoints-new-leader/2482258/daily0.7https://beta.crstoday.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/daily0.7https://beta.crstoday.com/news/retispec-and-topcon-healthcare-announce-collaboration-to-help-bring-eye-based-ai-diagnostic-tool-to-market/2482256/daily0.7https://beta.crstoday.com/news/fda-clears-aeye-healths-autonomous-ai-for-portable-diabetic-retinopathy-screening/2482255/daily0.7https://beta.crstoday.com/news/heidelberg-engineering-to-showcase-new-imaging-technology-at-arvo/2482254/daily0.7https://beta.crstoday.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/daily0.7https://beta.crstoday.com/news/qlaris-bio-completes-24-million-series-b-financing-round-to-advance-iop-lowering-drug-candidate-for-glaucoma/2482252/daily0.7https://beta.crstoday.com/news/prevent-blindness-announces-recipients-of-the-2024-jenny-pomeroy-award-and-the-rising-visionary-award/2482251/daily0.7https://beta.crstoday.com/news/bausch-lomb-presents-new-data-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting/2482250/daily0.7https://beta.crstoday.com/news/iantrek-presents-new-data-for-cyclopen-system-with-alloflo-carriers/2482249/daily0.7https://beta.crstoday.com/news/topcon-healthcare-names-ali-tafreshi-president-and-ceo/2483741/daily0.7https://beta.crstoday.com/news/lvpei-and-core-sign-partnership-agreement-for-vision-science-and-therapeutic-development/2483740/daily0.7https://beta.crstoday.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/daily0.7https://beta.crstoday.com/news/world-council-of-optometry-and-coopervision-partneron-myopia-management-navigator-educational-resource/2482245/daily0.7https://beta.crstoday.com/news/bausch-lomb-announces-results-of-study-examining-its-new-daily-nutritional-supplement-for-dry-eyes/2482244/daily0.7https://beta.crstoday.com/news/lep-biomedical-closes-pre-seed-funding-to-advance-hyaguard-platform/2482243/daily0.7https://beta.crstoday.com/news/alivi-health-unveils-new-vision-program/2483739/daily0.7https://beta.crstoday.com/news/retina-community-mourns-the-loss-of-ramin-tadayoni-md-phd/2482240/daily0.7https://beta.crstoday.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-axpaxli-in-diabetic-retinopathy-evaluated-in-phase-1-helios-clinical-trial/2482237/daily0.7https://beta.crstoday.com/news/aqueous-humor-proteome-database-established-by-medical-college-of-georgia/2482236/daily0.7https://beta.crstoday.com/news/schwind-names-lohith-shetty-head-of-global-marketing/2483738/daily0.7https://beta.crstoday.com/news/pantheon-vision-announces-two-pre-submission-meetings-with-the-fda/2482235/daily0.7https://beta.crstoday.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/daily0.7https://beta.crstoday.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/daily0.7https://beta.crstoday.com/news/ihealthscreen-awarded-us-patent-on-glaucoma-detection-based-on-ai-and-color-fundus-imaging/2482232/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-names-pravin-u-dugel-md-president-and-ceo/2482230/daily0.7https://beta.crstoday.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/daily0.7https://beta.crstoday.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/daily0.7https://beta.crstoday.com/news/medevise-consulting-achieves-iso13485-certification/2483737/daily0.7https://beta.crstoday.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/daily0.7https://beta.crstoday.com/news/oculis-appoints-snehal-shah-pharmd-as-president-of-research-development/2482225/daily0.7https://beta.crstoday.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/daily0.7https://beta.crstoday.com/news/orasis-introduces-soft-plug-extended-duration-180-t-tapered-plug/2482222/daily0.7https://beta.crstoday.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/daily0.7https://beta.crstoday.com/news/fda-approves-ocugens-ind-amendment-to-initiate-phase-3-trial-for-rp-gene-therapy/2482220/daily0.7https://beta.crstoday.com/news/cloudbreak-pharma-shares-data-from-survey-highlighting-patient-burden-of-pterygium/2482219/daily0.7https://beta.crstoday.com/news/nidek-announces-winners-of-the-4th-annual-image-of-the-year-award/2482217/daily0.7https://beta.crstoday.com/news/new-vr-solution-aims-to-democratize-ophthalmic-surgical-training/2482216/daily0.7https://beta.crstoday.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/daily0.7https://beta.crstoday.com/news/vialase-to-present-new-clinical-data-at-ascrs/2482214/daily0.7https://beta.crstoday.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/daily0.7https://beta.crstoday.com/news/wearing-glasses-boosts-income-by-a-third-in-low-income-communities-finds-landmark-new-study/2482212/daily0.7https://beta.crstoday.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/daily0.7https://beta.crstoday.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/daily0.7https://beta.crstoday.com/news/brill-establishes-subsidiary-in-the-united-states/2482209/daily0.7https://beta.crstoday.com/news/glaukos-receives-permanent-j-code-for-idose-tr/2482208/daily0.7https://beta.crstoday.com/news/powers-company-launches-lions-share-a-philanthropic-program-advancing-health-equity/2483736/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-the-results-of-the-3-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct/2482205/daily0.7https://beta.crstoday.com/news/aurion-biotech-to-present-clinical-data-at-ascrs/2482204/daily0.7https://beta.crstoday.com/news/centricity-vision-to-present-at-ascrs-and-eyecelerator/2482203/daily0.7https://beta.crstoday.com/news/nordic-pharma-to-present-data-on-lacrifill-canaliocular-gel-a-novel-therapy-for-dry-eye-at-ascrs/2482202/daily0.7https://beta.crstoday.com/news/biotissue-to-present-research-into-the-application-of-cryopreserved-amniotic-membrane-cam-at-ascrs/2482201/daily0.7https://beta.crstoday.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/daily0.7https://beta.crstoday.com/news/melt-pharmaceuticals-completes-stock-refinancing-to-support-further-development-of-melt-300/2482198/daily0.7https://beta.crstoday.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/daily0.7https://beta.crstoday.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/daily0.7https://beta.crstoday.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/daily0.7https://beta.crstoday.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/daily0.7https://beta.crstoday.com/news/csi-dry-eye-software-announces-the-release-of-version-50/2483735/daily0.7https://beta.crstoday.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/daily0.7https://beta.crstoday.com/news/vialase-closes-40-million-series-c-financing-to-advance-first-femtosecond-laser-for-the-treatment-of-glaucoma/2482192/daily0.7https://beta.crstoday.com/news/viatris-announces-us-launch-of-ryzumvi-for-the-reversal-of-mydriasis/2482191/daily0.7https://beta.crstoday.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-at-the-ascrs-annual-meeting/2482190/daily0.7https://beta.crstoday.com/news/aurion-biotech-announces-first-canadian-subject-dosed-in-phase-1-2-clinical-trial/2482189/daily0.7https://beta.crstoday.com/news/zeiss-to-showcase-new-3d-visualization-technology-and-surgical-innovations-at-ascrs/2482188/daily0.7https://beta.crstoday.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-association-2024-conference/2482187/daily0.7https://beta.crstoday.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/daily0.7https://beta.crstoday.com/news/ior-partners-aligns-with-the-joint-commission-accreditation-for-office-based-surgery-centers/2483734/daily0.7https://beta.crstoday.com/news/onpoint-vision-initiates-phase-1-trial-of-accurasee-intraocular-pseudophakic-capsular-lens-magnifier/2482184/daily0.7https://beta.crstoday.com/news/terry-kim-md-joins-alcon-as-chief-medical-officer-and-head-of-global-medical-safety/2482182/daily0.7https://beta.crstoday.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/daily0.7https://beta.crstoday.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/daily0.7https://beta.crstoday.com/news/study-compares-nanodropper-adaptor-versus-conventional-eye-drops-for-glaucoma/2482176/daily0.7https://beta.crstoday.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/daily0.7https://beta.crstoday.com/news/results-from-mont-blanc-phase-3-trial-of-nicoxs-ncx-470-in-glaucoma-published/2482173/daily0.7https://beta.crstoday.com/news/congress-passes-partial-adjustment-to-medicare-physician-payment/2482172/daily0.7https://beta.crstoday.com/news/study-pediatric-keratoconus-prevalence-higher-than-believed-may-change-care-approach/2482171/daily0.7https://beta.crstoday.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/daily0.7https://beta.crstoday.com/news/pandorum-technologies-secures-11-million-investment-to-advance-its-regenerative-therapy-for-corneal-blindness-to-clinical-phase/2482168/daily0.7https://beta.crstoday.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/daily0.7https://beta.crstoday.com/news/neurolens-restructures-leadership-team/2482165/daily0.7https://beta.crstoday.com/news/nordic-group-appoints-oculoplastic-surgeon-john-p-fezza-md-to-its-medical-advisory-board/2483733/daily0.7https://beta.crstoday.com/news/novasight-announces-publication-of-curesights-pivotal-study-of-one-year-follow-up-outcomes/2483732/daily0.7https://beta.crstoday.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/daily0.7https://beta.crstoday.com/news/mount-sinai-ophthalmologists-warn-about-dangers-of-looking-directly-at-the-sun/2483731/daily0.7https://beta.crstoday.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/daily0.7https://beta.crstoday.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/daily0.7https://beta.crstoday.com/news/bascom-palmer-outlines-moon-shot-whole-eye-transplant-research-initiative/2482155/daily0.7https://beta.crstoday.com/news/apellis-appoints-philip-ferrone-md-as-chief-medical-retina-advisor/2482154/daily0.7https://beta.crstoday.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/daily0.7https://beta.crstoday.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/daily0.7https://beta.crstoday.com/news/acrysof-iq-vivity-and-clareon-vivity-edof-iols-reach-1-million-implants-milestone/2482147/daily0.7https://beta.crstoday.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/daily0.7https://beta.crstoday.com/news/nicox-announces-presentation-of-data-on-ncx-470-at-the-2024-american-glaucoma-society-annual-meeting/2482143/daily0.7https://beta.crstoday.com/news/formosa-pharmaceuticals-receives-fda-approval-for-clobetasol-formulation-for-treatment-of-postoperative-inflammation-and-pain/2482142/daily0.7https://beta.crstoday.com/news/amring-pharmaceuticals-changes-name-to-nordic-pharma-under-new-owner/2482141/daily0.7https://beta.crstoday.com/news/glaukos-idose-tr-now-commercially-available/2482139/daily0.7https://beta.crstoday.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/daily0.7https://beta.crstoday.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/daily0.7https://beta.crstoday.com/news/palitin-misses-co-primary-endpoints-in-phase-3-trial-dry-eye-disease-candidate/2482136/daily0.7https://beta.crstoday.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/daily0.7https://beta.crstoday.com/news/pulsesight-therapeutics-launches-to-advance-non-viral-gene-therapies-for-severe-retinal-diseases/2482134/daily0.7https://beta.crstoday.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/daily0.7https://beta.crstoday.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/daily0.7https://beta.crstoday.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/daily0.7https://beta.crstoday.com/news/swiss-advanced-vision-launches-new-features-for-its-toric-calculator/2482130/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-announces-board-of-directors-and-leadership-updates/2482128/daily0.7https://beta.crstoday.com/news/abbvie-appoints-robert-a-michael-as-chief-executive-officer/2482125/daily0.7https://beta.crstoday.com/news/eversight-partners-with-emmecell-biotech-to-advance-ocular-cell-therapies/2482124/daily0.7https://beta.crstoday.com/news/vision-integrated-partners-completes-refinancing/2482123/daily0.7https://beta.crstoday.com/news/retinai-discovery-platform-launched-to-improve-workflows-referrals-and-patient-management-in-ophthalmology-and-optometry-clinics/2482122/daily0.7https://beta.crstoday.com/news/researchers-identify-genes-and-cell-types-that-may-have-causal-role-in-poag-formation/2482119/daily0.7https://beta.crstoday.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/daily0.7https://beta.crstoday.com/news/harrow-licenses-canadian-rights-to-apotex-for-five-branded-ophthalmic-drugs/2482117/daily0.7https://beta.crstoday.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/daily0.7https://beta.crstoday.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/daily0.7https://beta.crstoday.com/news/oculus-and-mainline-instruments-announce-uk-and-ireland-distribution-agreement/2483730/daily0.7https://beta.crstoday.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/daily0.7https://beta.crstoday.com/news/fda-gives-green-light-to-okyo-pharma-for-clinical-trial-design-for-ok-101-in-neuropathic-corneal-pain/2482109/daily0.7https://beta.crstoday.com/news/new-spiral-shaped-lens-designed-to-improve-vision-at-a-range-of-distances/2482108/daily0.7https://beta.crstoday.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/daily0.7https://beta.crstoday.com/news/beacon-therapeutics-announces-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-xlrp/2482105/daily0.7https://beta.crstoday.com/news/meridian-medical-launches-line-of-ophthalmic-lasers-in-the-us/2482104/daily0.7https://beta.crstoday.com/news/american-vision-partners-notifies-patients-of-cybersecurity-incident/2482103/daily0.7https://beta.crstoday.com/news/iridex-receives-european-patent-on-micropulse-technology/2482102/daily0.7https://beta.crstoday.com/news/shamir-launches-spark-4w-digital-electro-optic-measurement-system/2482101/daily0.7https://beta.crstoday.com/news/nicox-announces-presentations-at-the-upcoming-arvo-annual-meeting-2024/2482100/daily0.7https://beta.crstoday.com/news/adverum-biotechnologies-raises-1275-million-to-advance-gene-therapy-pipeline/2482099/daily0.7https://beta.crstoday.com/news/bausch-lomb-to-present-scientific-data-and-analyses-on-xipere-at-macula-society-annual-meeting/2482098/daily0.7https://beta.crstoday.com/news/toku-obtains-ce-and-ukca-marks-for-ai-cardiovascular-risk-assessments-through-the-eye/2482096/daily0.7https://beta.crstoday.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/daily0.7https://beta.crstoday.com/news/fda-warns-consumers-of-contaminated-copycat-versions-of-lumify-eye-drops/2482094/daily0.7https://beta.crstoday.com/news/martin-spencer-md-receives-the-2024-ascrs-foundation-chang-crandall-humanitarian-award/2483729/daily0.7https://beta.crstoday.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/daily0.7https://beta.crstoday.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/daily0.7https://beta.crstoday.com/news/american-academy-of-ophthalmology-issues-warning-on-the-dangers-of-eye-color-changing-procedures/2482088/daily0.7https://beta.crstoday.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/daily0.7https://beta.crstoday.com/news/ascendis-pharma-forms-new-ophthalmology-company-eyconis/2482086/daily0.7https://beta.crstoday.com/news/ocucell-announces-funding-from-the-eye-bank-association-of-america/2482084/daily0.7https://beta.crstoday.com/news/mass-eye-and-ear-retinal-imaging-and-genetics-data-used-to-predict-future-disease-risk/2482082/daily0.7https://beta.crstoday.com/news/iridex-enrolls-first-patient-in-micropulse-tlt-study-in-collaboration-with-imperial-college-healthcare-nhs-trust/2482081/daily0.7https://beta.crstoday.com/news/chris-throckmorton-named-chief-executive-officer-of-eyecare-partners/2483728/daily0.7https://beta.crstoday.com/news/world-council-of-optometry-hosts-myopia-management-virtual-event-focused-on-latin-america/2482080/daily0.7https://beta.crstoday.com/news/rayners-rayone-emv-receives-health-canada-approval/2482076/daily0.7https://beta.crstoday.com/news/digitaloptometrics-launches-dot-translation-service/2482073/daily0.7https://beta.crstoday.com/news/mega-analysis-identifies-gene-variants-associated-with-glaucoma-in-people-of-african-ancestry/2482072/daily0.7https://beta.crstoday.com/news/sydnexis-names-erin-horn-as-vice-president-head-of-market-access/2482071/daily0.7https://beta.crstoday.com/news/iuvo-bioscience-acquires-promedica-international-to-expand-ophthalmic-clinical-cro-services/2482070/daily0.7https://beta.crstoday.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/daily0.7https://beta.crstoday.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/daily0.7https://beta.crstoday.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/daily0.7https://beta.crstoday.com/news/nidek-and-orbis-international-partner-to-scale-up-artificial-intelligence-eye-screenings-in-vietnam/2482060/daily0.7https://beta.crstoday.com/news/amring-pharmaceuticals-names-jai-g-parekh-md-chief-commercial-officer-eye-care-us/2482059/daily0.7https://beta.crstoday.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/daily0.7https://beta.crstoday.com/news/arpa-h-launches-thea-research-program-for-whole-eye-transplantation-to-restore-vision-for-the-blind/2483727/daily0.7https://beta.crstoday.com/news/iridex-532-and-iridex-577-lasers-launched-in-united-states/2482054/daily0.7https://beta.crstoday.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/daily0.7https://beta.crstoday.com/news/zeiss-visumax-800-with-smile-pro-software-approved-by-fda/2482056/daily0.7https://beta.crstoday.com/news/nidek-launches-mirante-scanning-laser-ophthalmoscope-in-the-united-states/2482052/daily0.7https://beta.crstoday.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/daily0.7https://beta.crstoday.com/news/gentex-acquires-esight/2482048/daily0.7https://beta.crstoday.com/news/okyo-pharmas-ok-101-solution-evaluated-in-fih-phase-2-trial-for-dry-eye-disease/2483726/daily0.7https://beta.crstoday.com/news/bausch-lomb-receives-fda-approval-for-teneo-excimer-laser-platform-for-myopia-and-myopic-astigmatism-lasik/2482047/daily0.7https://beta.crstoday.com/news/eylea-8-mg-approved-in-eu/2482046/daily0.7https://beta.crstoday.com/news/study-indicates-a-potential-treatment-for-corneal-endothelial-disease-reducing-the-need-for-corneal-transplants/2482045/daily0.7https://beta.crstoday.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/daily0.7https://beta.crstoday.com/news/prevent-blindness-opens-nominations-for-the-2024-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award/2482043/daily0.7https://beta.crstoday.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/daily0.7https://beta.crstoday.com/news/ocuphire-pharma-receives-fda-agreement-for-phase-3-trial-of-phentolamine-solution-for-the-treatment-of-decreased-visual-acuity-under-dim-light-conditions/2482041/daily0.7https://beta.crstoday.com/news/bausch-lomb-and-glaucoma-research-foundation-launch-faces-of-glaucoma-campaign/2482039/daily0.7https://beta.crstoday.com/news/melt-pharmaceuticals-provides-corporate-update-on-melt300-sedation-tablet/2482038/daily0.7https://beta.crstoday.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/daily0.7https://beta.crstoday.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/daily0.7https://beta.crstoday.com/news/regeneron-wins-patent-case-to-extend-eylea-protection/2482035/daily0.7https://beta.crstoday.com/news/lsu-health-discovery-may-open-new-therapeutic-avenues-for-degenerative-diseases-of-the-brain-and-eye/2482034/daily0.7https://beta.crstoday.com/news/study-identifies-visual-system-protein-for-circadian-rhythm-stability/2482033/daily0.7https://beta.crstoday.com/news/lupin-receives-fda-approval-for-generic-loteprednol-etabonate-ophthalmic-suspension/2482032/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-withdrawal-of-final-lcds-on-micro-invasive-glaucoma-surgery-from-five-medicare-administrative-contractors/2482031/daily0.7https://beta.crstoday.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/daily0.7https://beta.crstoday.com/news/visiox-pharmaceuticals-to-be-listed-on-nasdaq-through-combination-with-powerup-acquisition/2482029/daily0.7https://beta.crstoday.com/news/cellusion-receives-fda-orphan-drug-designation-for-cls001/2482028/daily0.7https://beta.crstoday.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/daily0.7https://beta.crstoday.com/news/cell-types-in-the-eye-have-ancient-evolutionary-origins/2482026/daily0.7https://beta.crstoday.com/news/johnson-johnson-buys-gene-therapy-for-x-linked-retinitis-pigmentosa-from-meiragtx/2482024/daily0.7https://beta.crstoday.com/news/ecm-therapeutics-collaborates-with-the-university-of-pittsburgh-vision-institute-to-advance-technology-for-optic-nerve-repair/2482023/daily0.7https://beta.crstoday.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/daily0.7https://beta.crstoday.com/news/nordic-pharma-completes-acquisition-of-visant-medical-plans-to-launch-lacrifill-in-the-us-for-dry-eye-disease/2482021/daily0.7https://beta.crstoday.com/news/pixium-vison-date-scheduled-for-decision-on-adoption-of-a-sale-plan/2482020/daily0.7https://beta.crstoday.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/daily0.7https://beta.crstoday.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/daily0.7https://beta.crstoday.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/daily0.7https://beta.crstoday.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/daily0.7https://beta.crstoday.com/news/glaukos-receives-fda-approval-of-idose-tr-intracameral-implant/2482009/daily0.7https://beta.crstoday.com/news/genentech-names-ashley-magargee-as-ceo/2482008/daily0.7https://beta.crstoday.com/news/prevent-blindness-president-ceo-jeff-todd-to-lead-2024-national-health-council-board-of-directors/2482007/daily0.7https://beta.crstoday.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/daily0.7https://beta.crstoday.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/daily0.7https://beta.crstoday.com/news/new-report-calls-for-a-national-eye-care-plan-for-england-to-address-surging-patient-demand/2482003/daily0.7https://beta.crstoday.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/daily0.7https://beta.crstoday.com/news/zeiss-announces-new-biometry-mastery-courses-in-2024/2482000/daily0.7https://beta.crstoday.com/news/national-eye-institute-selects-richard-lee-md-phd-as-clinical-director/2481999/daily0.7https://beta.crstoday.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/daily0.7https://beta.crstoday.com/news/ihealthscreen-announces-mhra-certification-and-registration-for-ipredict-automated-ai-system/2481997/daily0.7https://beta.crstoday.com/news/horus-pharma-strengthens-its-international-expansion/2481996/daily0.7https://beta.crstoday.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/daily0.7https://beta.crstoday.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/daily0.7https://beta.crstoday.com/news/ciliatech-releases-new-design-of-glaucoma-surgical-device-cid/2481993/daily0.7https://beta.crstoday.com/news/corza-medical-opens-ophthalmology-center-of-technology-and-innovation/2481992/daily0.7https://beta.crstoday.com/news/hcp-cureblindness-performs-first-tissue-transplant-in-eritrea/2483725/daily0.7https://beta.crstoday.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/daily0.7https://beta.crstoday.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/daily0.7https://beta.crstoday.com/news/harrow-completes-transfer-of-the-triesence-new-drug-application/2481986/daily0.7https://beta.crstoday.com/news/aldeyra-receives-fda-complete-response-letter-on-new-drug-application-for-reproxalap-in-dry-eye-disease/2483724/daily0.7https://beta.crstoday.com/news/ocuphire-pharma-reports-inducement-grant-for-new-coo/2481985/daily0.7https://beta.crstoday.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/daily0.7https://beta.crstoday.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/daily0.7https://beta.crstoday.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/daily0.7https://beta.crstoday.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/daily0.7https://beta.crstoday.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/daily0.7https://beta.crstoday.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/daily0.7https://beta.crstoday.com/news/pixium-vision-receives-takeover-offer/2481976/daily0.7https://beta.crstoday.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/daily0.7https://beta.crstoday.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/daily0.7https://beta.crstoday.com/news/keeler-usa-long-grove-pharmaceuticals-enter-into-a-distribution-agreement-for-ak-fluor/2481972/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/daily0.7https://beta.crstoday.com/news/keralink-international-provides-25-million-in-seed-funding-to-enable-development-of-bioengineered-corneal-implants/2481970/daily0.7https://beta.crstoday.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/daily0.7https://beta.crstoday.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/daily0.7https://beta.crstoday.com/news/orcam-technologies-unveils-orcam-read-3-ai-driven-solution-for-people-with-low-vision-and-visual-impairments/2481965/daily0.7https://beta.crstoday.com/news/oig-publishes-general-compliance-program-guidance-for-the-health-care-industry/2481964/daily0.7https://beta.crstoday.com/news/study-racial-disparities-in-glaucoma-care-persist-regardless-of-socioeconomic-status/2481961/daily0.7https://beta.crstoday.com/news/worlds-first-whole-eye-partial-face-transplant-performed-at-nyu-langone-health/2481958/daily0.7https://beta.crstoday.com/news/visionix-announces-strategic-partnership-with-2020now/2481957/daily0.7https://beta.crstoday.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/daily0.7https://beta.crstoday.com/news/bausch-lomb-receives-cpt-category-1-code-for-xipere-from-the-american-medical-association/2481954/daily0.7https://beta.crstoday.com/news/bausch-lomb-announces-publication-of-miebo-phase-3-extension-trial-data/2481953/daily0.7https://beta.crstoday.com/news/ascrs-names-abigail-markward-new-executive-director/2481952/daily0.7https://beta.crstoday.com/news/lumenis-optiplus-dual-frequency-rf-energy-device-launched/2481949/daily0.7https://beta.crstoday.com/news/iris-registry-based-study-evaluates-side-effect-of-semaglutide-weight-loss-drug-on-diabetic-retinopathy/2481947/daily0.7https://beta.crstoday.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/daily0.7https://beta.crstoday.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/daily0.7https://beta.crstoday.com/news/adverums-ixo-vec-for-wet-amd-evaluated-in-3-year-data-from-optic-extension-study/2481951/daily0.7https://beta.crstoday.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/daily0.7https://beta.crstoday.com/news/topcon-introduces-tempo-perimeter-at-aao-2023/2481942/daily0.7https://beta.crstoday.com/news/ace-vision-group-adds-four-ophthalmologists-to-medical-advisory-board-launches-new-corporate-and-medical-affairs-websites/2481941/daily0.7https://beta.crstoday.com/news/verana-health-partners-with-foundation-fighting-blindness-to-integrate-genetic-testing-data-into-real-world-evidence-research/2481940/daily0.7https://beta.crstoday.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/daily0.7https://beta.crstoday.com/news/ace-vision-group-names-rob-kissling-md-as-chief-medical-officer-1/2481938/daily0.7https://beta.crstoday.com/news/ora-and-blindcan-film-festival-unveil-the-blind-canvas-project-using-ai-to-visualize-the-human-experience-of-blindness/2481937/daily0.7https://beta.crstoday.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/daily0.7https://beta.crstoday.com/news/modmed-introduces-single-screen-soap-notes/2483723/daily0.7https://beta.crstoday.com/news/johnson-johnson-focuses-on-discussions-data-diversity-and-innovation-to-help-advance-modern-practices-and-patient-outcomes-at-aao/2483722/daily0.7https://beta.crstoday.com/news/fda-grants-breakthrough-device-status-to-tokus-patented-cardiovascular-risk-ai-clair-platform/2481934/daily0.7https://beta.crstoday.com/news/ada-and-genentech-launch-campaign-to-raise-awareness-and-address-inequity-in-diabetes-related-eye-disease/2481933/daily0.7https://beta.crstoday.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/daily0.7https://beta.crstoday.com/news/centricity-vision-announces-commercial-launch-of-zeptolink-iol-positioning-system-at-aao/2481931/daily0.7https://beta.crstoday.com/news/alcon-showcases-cloud-based-planning-and-digital-technologies-during-aao-2023/2481930/daily0.7https://beta.crstoday.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/daily0.7https://beta.crstoday.com/news/ocuphire-pharma-announces-appointment-of-george-magrath-md-ms-as-chief-executive-officer-and-director/2481927/daily0.7https://beta.crstoday.com/news/okogen-initiates-phase-2b-clinical-trial-for-acute-infectious-conjunctivitis/2481926/daily0.7https://beta.crstoday.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/daily0.7https://beta.crstoday.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/daily0.7https://beta.crstoday.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/daily0.7https://beta.crstoday.com/news/oertli-opens-new-lean-factory-building-in-berneck-eastern-switzerland/2481922/daily0.7https://beta.crstoday.com/news/vialase-completes-enrollment-for-the-via-002-trial-of-the-vialase-laser-to-treat-primary-open-angle-glaucoma/2481921/daily0.7https://beta.crstoday.com/news/bausch-lomb-launches-seena-optical-biometry-and-topography-system-in-the-united-states/2481920/daily0.7https://beta.crstoday.com/news/fda-warns-consumers-not-to-purchase-or-use-26-brands-of-eye-drops/2481919/daily0.7https://beta.crstoday.com/news/opthea-appoints-us-based-leadership-with-fred-guerard-as-ceo-and-peter-lang-as-cfo/2481918/daily0.7https://beta.crstoday.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-at-american-academy-of-ophthalmology-annual-meeting/2481916/daily0.7https://beta.crstoday.com/news/zeiss-expand-its-clinical-workflows-and-digital-portfolio-at-aao-2023/2481915/daily0.7https://beta.crstoday.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-survey-highlights-barriers-faced-by-women-in-ophthalmology/2483721/daily0.7https://beta.crstoday.com/news/aurion-biotech-announces-first-subject-dosed-in-us-phase-1-2-clinical-trial/2481908/daily0.7https://beta.crstoday.com/news/bausch-lomb-introduces-new-surgical-planning-software-for-eyetelligence-platform/2481907/daily0.7